Literature DB >> 35506112

Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry.

Paula Appenzeller1, Mona Lichtblau1, Charlotte Berlier1, John-David Aubert2, Andrea Azzola3, Jean-Marc Fellrath4, Thomas Geiser5, Frederic Lador6, Susanne Pohle7, Isabelle Opitz8, Markus Schwerzmann5, Hans Stricker9, Michael Tamm10, Stéphanie Saxer1, Silvia Ulrich1.   

Abstract

Pulmonary hypertension (PH), especially pulmonary arterial and chronic thromboembolic pulmonary hypertension (PAH/CTEPH), are rare and progressive conditions. Despite recent advances in treatment and prognosis, PH is still associated with impaired quality of life and survival. Long-term PH-registry data provide information on the changing PH-epidemiology and may help to direct resources to patient's needs. This retrospective analysis of the Swiss Pulmonary Hypertension Registry includes patients newly diagnosed with PH (mainly PAH/CTEPH) registered from January 2001 to June 2019 at 13 Swiss hospitals. Patient characteristics (age, body mass index, gender, diagnosis), hemodynamics at baseline, treatment, days of follow-up, and events (death, transplantation, pulmonary endarterectomy, or loss to follow-up) at last visit were analyzed. Patients were stratified into four time periods according to their date of diagnosis. Survival was analyzed overall and separately for PAH/CTEPH and time periods. 1427 PH patients were included (thereof 560 PAH, 383 CTEPH). Over the years, age at baseline (mean ± SD) significantly increased from 59 ± 14 years in 2001-2005 to 66 ± 14 years in 2016-2019 (p < 0.001) while the gender distribution tended toward equality. Mean pulmonary artery pressure and pulmonary vascular resistance significantly decreased over time (from 46 ± 15 to 41 ± 11 mmHg, respectively, 9 ± 5 to 7 ± 4 WU, p < 0.001). Three-year survival substantially increased over consecutive periods from 69% to 91% (for PAH 63%-95%, for CTEPH 86%-93%) and was poorer in PAH than CTEPH independently of time period (p < 0.001). Most patients were treated with mono- or combination therapy and an increasing number of CTEPH underwent pulmonary endarterectomy (40% 2016-2019 vs. 15% 2001-2005). This long-term PH registry reveals that over two decades of observation, newly diagnosed patients are older, less predominantly female, have less impaired hemodynamics and a better survival.
© 2021 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute.

Entities:  

Keywords:  chronic thromboembolic pulmonary hypertension; pulmonary arterial hypertension; survival

Year:  2022        PMID: 35506112      PMCID: PMC9052988          DOI: 10.1002/pul2.12001

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   2.886


  30 in total

1.  Pulmonary arterial hypertension in France: results from a national registry.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaici; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Gérald Simonneau
Journal:  Am J Respir Crit Care Med       Date:  2006-02-02       Impact factor: 21.405

2.  Long-term data from the Swiss pulmonary hypertension registry.

Authors:  Séverine Mueller-Mottet; Hans Stricker; Guido Domenighetti; Guido Domeninghetti; Andrea Azzola; Thomas Geiser; Markus Schwerzmann; Daniel Weilenmann; Otto Schoch; Jean-Marc Fellrath; Thierry Rochat; Frederic Lador; Maurice Beghetti; Laurent Nicod; John-David Aubert; Vladimir Popov; Rudolf Speich; Stephan Keusch; Elisabeth Hasler; Lars C Huber; Peter Grendelmeier; Michael Tamm; Silvia Ulrich
Journal:  Respiration       Date:  2015-01-31       Impact factor: 3.580

3.  ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre.

Authors:  J Hurdman; R Condliffe; C A Elliot; C Davies; C Hill; J M Wild; D Capener; P Sephton; N Hamilton; I J Armstrong; C Billings; A Lawrie; I Sabroe; M Akil; L O'Toole; D G Kiely
Journal:  Eur Respir J       Date:  2011-09-01       Impact factor: 16.671

4.  Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.

Authors:  Chao-Jie He; Shao-Jie Chen; Jie Wang; Chun-Yan Zhu; Yue-Hui Yin
Journal:  Pulm Pharmacol Ther       Date:  2015-04-02       Impact factor: 3.410

Review 5.  Pulmonary arterial hypertension: epidemiology and registries.

Authors:  Michael D McGoon; Raymond L Benza; Pilar Escribano-Subias; Xin Jiang; Dave P Miller; Andrew J Peacock; Joanna Pepke-Zaba; Tomas Pulido; Stuart Rich; Stephan Rosenkranz; Samy Suissa; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

6.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

Authors:  David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

7.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

8.  Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.

Authors:  Marc Humbert; Christophe Guignabert; Sébastien Bonnet; Peter Dorfmüller; James R Klinger; Mark R Nicolls; Andrea J Olschewski; Soni S Pullamsetti; Ralph T Schermuly; Kurt R Stenmark; Marlene Rabinovitch
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

9.  Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update.

Authors:  Anton Vonk Noordegraaf; Kelly Marie Chin; François Haddad; Paul M Hassoun; Anna R Hemnes; Susan Roberta Hopkins; Steven Mark Kawut; David Langleben; Joost Lumens; Robert Naeije
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 10.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Alessandra Manes; Luca Negro; Massimiliano Palazzini; Maria Letizia Bacchi-Reggiani; Angelo Branzi
Journal:  Eur Heart J       Date:  2009-01-20       Impact factor: 29.983

View more
  1 in total

1.  Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry.

Authors:  Paula Appenzeller; Mona Lichtblau; Charlotte Berlier; John-David Aubert; Andrea Azzola; Jean-Marc Fellrath; Thomas Geiser; Frederic Lador; Susanne Pohle; Isabelle Opitz; Markus Schwerzmann; Hans Stricker; Michael Tamm; Stéphanie Saxer; Silvia Ulrich
Journal:  Pulm Circ       Date:  2022-01-05       Impact factor: 2.886

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.